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Abstract The urokinase-type plasminogen activator uPA-R can
regulate integrin functions by associating with several types of L-
subunit. We have recently shown that normal thyroid TAD-2
cells express both a native and a cleaved form of uPA-R which
lacks the binding domain for uPA. We found this cleaved form to
be present in reduced amounts in papillary and follicular thyroid
carcinoma cells and completely absent in cells derived from an
anaplastic thyroid carcinoma (ARO). We now report that in
normal thyroid cells the intact form of uPA-R strongly associates
with L-1 integrins, whereas its cleaved form does not. uPA-R
expressed by ARO cells shows a stronger resistance to the
cleavage mediated by uPA, plasmin and chymotrypsin than does
uPA-R expressed by normal thyroid cells. This resistance to
cleavage correlates with the higher level of glycosylation of uPA-
R of ARO cells as compared to that of cleavable uPA-R of
normal thyroid cells. These results suggest that uPA-R cleavage,
which occurs in several cell types, represents a mechanism
regulating the interactions of uPA-R with integrins and, possibly,
the subsequent integrin-mediated cell adhesion. Moreover we
hypothesize that glycosylation regulates uPA-R cleavage and,
indirectly, its interaction with integrins.
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1. Introduction
Many events related to tumor growth and metastasis de-
pend on the ability of cells to modulate their adherence to
adjacent cells or to the surrounding extracellular matrix
(ECM) [1]. In order to promote migration and tissue invasion
tumor cells must strictly regulate their adherence to ECM and
extracellular proteolysis. Interestingly, the receptor for the
urokinase-type plasminogen activator (uPA-R) is able to ful¢l
both of these functions [2^4]. The role of uPA-R was tradi-
tionally seen as the concentration of the proteolytic activity of
its ligand (uPA) on the cell surface, thus amplifying plasmin-
ogen activation [5]. Recently uPA-R has also been shown to
be directly involved in cell adhesion to ECM. In fact, uPA-R
can act as a receptor for vitronectin (VTN), a component of
ECM associated with malignant tumors [6], and interacts with
integrins of the L1, L2 and L3 families [7^9] ; uPA-R’s inter-
action with VTN can be increased by binding uPA, independ-
ently of its enzymatic activity [6], and, ¢nally, its association
with L-integrins can be modulated by ECM components
themselves [9].
uPA-R is a highly glycosylated single chain protein. It con-
sists of three di¡erent domains: domain 1 (D1), which binds
uPA, domain 3 (D3), anchoring uPA-R to the cell surface by a
glycophosphoinositol (GPI) tail, and domain 2 (D2), connect-
ing D1 to D3 [3]. The linker region connecting domains 1 and
2 can be cleaved by several proteases such as plasmin, chymo-
trypsin and uPA itself at physiological concentrations [10,11].
The cleavage occurs in several cell lines, thus expressing on
the cell surface the cleaved form of uPA-R (D2+D3), lacking
the uPA binding domain (D1) [12]. Since uPA-R (D2+D3)
cannot bind uPA it has been proposed that the cleavage
may be a regulatory step in the cell surface-associated plas-
minogen activation cascade [11]. Soluble cleaved uPA-R is
also unable to bind VTN, even though the binding site for
this protein has been assigned to the D2+D3 domains [13].
We have recently characterized the plasminogen activation
system in thyroid cells [14], showing that normal thyroid cells
express both intact uPA-R and its cleaved form. Interestingly,
the cleaved form of uPA-R is largely expressed in normal
cells, decreases in cells derived from more aggressive thyroid
carcinomas and disappears in anaplastic carcinoma cells.
In the present report, we investigated whether uPA-R cleav-
age can regulate its interactions with integrin adhesion mole-
cules in thyroid cells, and how cell surface uPA-R cleavage, in
turn, can be regulated.
2. Materials and methods
2.1. Reagents
Mouse monoclonal antibodies R4, recognizing an epitope on uPA-
R domains 2+3, S1, directed to reduced and alkylated uPA-R and the
anti-uPA cl5 [11] were kindly provided by Dr. G. Hoyer-Hansen
(Finsen Laboratory, Copenhagen, Denmark). Rabbit polyclonal anti-
bodies against L1 and L3 integrin chains were provided by Dr. G.
Tarone (University of Turin, Italy) and uPA-R cDNA by Dr. M.P.
Stoppelli (IIGB, CNR, Naples, Italy). Enhanced chemiluminescence
(ECL) detection kit was from Amersham International (Amersham,
UK) and Lipofectamine from Gibco BRL (Life Technologies, MD,
USA). Polyvinylidene £uoride (PVDF) ¢lters were from Millipore
(Windsor, MA, USA) and protein A-Sepharose from Pharmacia
(Uppsala, Sweden). Collagen, laminin, vitronectin and ¢bronectin
were from Collaborative Research (Bedford, MA, USA).
2.2. Cell culture
TAD-2 and ARO cell lines were derived from human fetal thyroid
cells [15] and from anaplastic thyroid carcinoma [16] respectively.
Both cell lines were cultured in RPMI 1640 medium (Flow, McLean,
VA, USA) supplemented with 10% fetal calf serum (Gibco).
2.3. Immunoprecipitation
Immunoprecipitation was performed as previously described [7].
Cells (2.5U106/sample) were washed twice with microtubule stabiliza-
tion bu¡er (0.1 M PIPES, pH 6.9, 2 M glycerol, 1 mM EGTA, 1 mM
magnesium acetate), and then extracted in 0.2% Triton X-100 supple-
mented with protease inhibitors. The insoluble residue, enriched in
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cytoskeleton-associated proteins, was solubilized in RIPA bu¡er
(150 mM NaCl, 50 mM Tris-HCl, pH 7.5, 1% deoxycholate, 0.1%
SDS, 1% Triton X-100 and protease inhibitors), and preincubated
with non-immune serum and protein A-Sepharose, for 2 h at 4‡C.
After centrifugation, supernatants were incubated with 3 Wl of antisera
to L1 and L3 integrins or with 3 Wl of non-immune serum, for 2 h at
4‡C. After 30 min incubation with protein A-Sepharose, immunopre-
cipitates were washed, and analyzed by 9% SDS-PAGE and Western
blot, using R4 monoclonal anti-uPA-R antibody, at a concentration
of 1 Wg/ml.
2.4. Western blot
Cells were lysed in 1% Triton X-100 in PBS and protein content
was measured by a colorimetric assay (Bio-Rad, Richmond, CO,
USA). 50 Wg of total proteins or immunoprecipitated samples (see
above) were electrophoresed on a 9% SDS-PAGE and transferred
onto a PVDF membrane. The membrane was blocked with 5%
non-fat dry milk, and probed with R4 anti-uPA-R antibody, at a
concentration of 1 Wg/ml. Finally, washed ¢lters were incubated
with horseradish peroxidase-conjugated anti-mouse antibody (Bio-
Rad) and detected by ECL.
2.5. Transfection
uPA-R cDNA was cloned in the EcoRI site of pcDNA3 (Invitro-
gen, San Diego, CA, USA) and the resulting plasmid was named
uPA-R-pcDNA3. 5U106 cells, cultured overnight in 100 mm tissue
culture dishes, were transiently transfected with 10 Wg of uPA-R-
pcDNA3 or control vector pcDNA3 and 60 Wl of Lipofectamine
for 5 h at 37‡C (5% CO2). Cells were analyzed at 72 h after trans-
fection.
2.6. Deglycosylation assay
Cells (5U106) were lysed in 0.5 ml of 1% Triton X-100 supple-
mented with protease inhibitors. Lysates were then boiled for 3 min
in the presence of 0.5% SDS and 1.6 mM dithiothreitol. Aliquots of
the denatured samples (20 Wl) were adjusted to include 200 mM so-
dium phosphate, pH 8.6, 1.5% Triton X-100, 10 mM EDTA, up to a
volume of 60 Wl. The samples were then incubated with or without
2 units of N-glycosidase F at 37‡C for 20 h. Finally they were treated
with 25 mM iodoacetamide for 1 h at 20‡C and analyzed by Western
blot using 10 Wg/ml of the monoclonal antibody (S1) which reacts with
reduced and alkylated uPA-R.
3. Results
3.1. Cleaved uPA-R and integrins
Normal thyroid TAD-2 cells express equivalent amounts of
both native and cleaved forms of uPA-R (Fig. 1, lane 1) and
detectable amounts of L1 and L3 integrins [17]. We investi-
gated whether uPA-R cleavage in this cell line can interfere
with its association to these integrins.
RIPA lysates of TAD-2 cells, enriched in cytoskeleton-as-
sociated proteins [7], were immunoprecipitated with polyclo-
nal antisera against L1 and L3 chains and analyzed by West-
ern blot, using R4 monoclonal antibody, which recognizes
both forms of uPA-R. ECL staining showed the presence of
intact uPA-R (MW 50 kDa) in the samples immunoprecipi-
tated with anti-L1 (Fig. 2, lane 3), whereas the receptor was
undetectable in the sample immunoprecipitated with anti-L3
antibodies (Fig. 2, lane 2) and in the control sample immu-
noprecipitated with non-immune serum (Fig. 2, lane 1).
Cleaved uPA-R (MW 35 kDa) was absent in all immunopre-
cipitated samples (Fig. 2, lanes 1^3). However, the signal of
intact uPA-R was extremely weak, just above the threshold of
detection. It is therefore possible that slightly lower amounts
of cleaved uPA-R, coprecipitated with L1 integrins, could
have escaped observation. In order to exclude this possibility,
uPA-R was overexpressed in TAD-2 cells by transfection with
uPA-R cDNA. Transfected cells expressed very high amounts
of both forms of uPA-R (Fig. 3, lane 1), to such an extent that
Fig. 1. uPA-R in normal thyroid cells. Biotinylated cell surface anti-
gens of TAD-2 cells were immunoprecipitated with 10 Wg/ml of R4
anti-uPA-R monoclonal antibody (lane 1) or 10 Wg/ml of non-im-
mune Ig (lane 2). Immunoprecipitated samples were electrophoresed
on 9% SDS-PAGE and transferred onto PVDF membrane. Biotinyl-
ated antigens were detected by streptavidin and ECL.
Fig. 2. Cleaved uPA-R and integrins. TAD-2 cell lysates were im-
munoprecipitated with polyclonal antisera against L3 (lane 2) and
L1 (lane 3) chains or with non-immune serum (lane 1). Immunopre-
cipitated samples were electrophoresed on 9% SDS-PAGE and ana-
lyzed by Western-blot with 1 Wg/ml of R4 anti-uPA-R antibody.
FEBS 22752 11-10-99
N. Montuori et al./FEBS Letters 460 (1999) 32^36 33
the amount of endogenous uPA-R became negligible (Fig. 3,
lane 2). Lysates of transfected TAD-2 cells were immunopre-
cipitated with an anti-L1 antiserum and analyzed by Western
blot with R4 anti-uPA-R antibody. Large amounts of intact
uPA-R co-precipitated with L1 integrins, giving rise to a
strong and readily detectable signal, whereas cleaved uPA-R
was present in a much smaller amount (Fig. 3, lane 3).
These results clearly show that the intact form of uPA-R
(50 kDa) strongly associates with L1 integrins, whereas its
cleaved form interacts poorly with them.
3.2. Resistance of uPA-R to cleavage
Since cleavage of uPA-R could regulate uPA-R-integrin in-
teractions, we investigated whether the cleavage itself is regu-
lated by the cell.
We have previously shown that cleaved uPA-R is absent in
a cell line derived from an anaplastic thyroid carcinoma
(ARO cells), expressing only the intact form of uPA-R with
a MW slightly higher (55 kDa) than that of uPA-R of TAD-2
cells (50 kDa) [14]. We therefore investigated whether the
absence of cleaved uPA-R was the result of a resistance of
the intact receptor to proteolytic cleavage.
Cl5, an antibody able to inactivate endogenous uPA,
strongly decreases the formation of cleaved uPA-R on the
cell surface of monocyte-like cell lines [11]. Therefore TAD-
2 and ARO cells were grown in the presence of cl5, in order to
obtain TAD-2 cells expressing most uPA-R in the intact form,
as well as ARO cells (Fig. 4, lanes 1^2, 7^8). Cl5-treated cells
were incubated with uPA, plasmin and chymotrypsin, en-
zymes able to cleave the linker region of domains 1 and 2
of uPA-R [10]. Cells were then lysed and analyzed by Western
blot with R4 anti-uPA-R antibody. uPA and plasmin partially
cleaved uPA-R of TAD-2 cells, causing a decrease in the
amount of the intact form and a proportional increase of
the amount of the cleaved form (Fig. 4, lanes 3 and 4); higher
doses of plasmin and chymotrypsin almost completely cleaved
uPA-R, which appeared only in the cleaved form (Fig. 4, lanes
5 and 6).
In ARO cells, which produce only traces of uPA [14], no
modi¢cations of the higher molecular weight uPA-R were
observed after treatment with cl5, as expected (Fig. 4, lanes
7 and 8). uPA and low doses of plasmin did not cleave uPA-R
(Fig. 4, lanes 9 and 10), and higher doses of plasmin and
chymotrypsin were only partially e¡ective in cleaving the re-
ceptor (Fig. 4, lanes 11 and 12), whereas high doses of plas-
min and chymotrypsin seemed to induce a broader degrada-
tion of uPA-R, since the decrease of the intact form did not
correspond to a proportional increase of a single cleaved
form, as observed in TAD-2 cells (Fig. 4, lanes 5^6, 11^12).
All together, these results indicate that uPA-R expressed by
ARO cells is particularly resistant to uPA-, plasmin- and chy-
motrypsin-dependent cleavage as compared to uPA-R of nor-
mal thyroid cells, which can be cleaved very e⁄ciently by all
these proteolytic enzymes.
3.3. uPA-R glycosylation and cleavage resistance
The di¡erence in molecular weight between cleavage-resist-
ant uPA-R, expressed by ARO cells, and cleavable uPA-R of
TAD-2 cells could be due to a di¡erent level of glycosylation.
Therefore TAD-2 and ARO cell lysates were incubated with
or without endoglycosidase F (PGNase F) and analyzed by
Western blot with a monoclonal antibody, S1, recognizing
both forms of reduced and alkylated uPA-R. Intact uPA-Rs
in untreated TAD-2 and ARO samples migrated di¡erently in
a 9% SDS-PAGE, showing a molecular weight di¡erence of
about 5 kDa, as expected (Fig. 5, lanes 1 and 2). After degly-
cosylation with PGNase F, intact uPA-R of the two cell lines
showed the same molecular weight (30 kDa) (Fig. 5, lanes 3
and 4), which suggests a higher glycosylation of uPA-R of
ARO cells than of uPA-R expressed by TAD-2 cells. The
molecular weight of the cleaved form of uPA-R expressed
Fig. 3. Cleaved uPA-R and L1 integrins in transfected TAD-2 cells.
TAD-2 cells, transfected with uPAR-pcDNA3 (lanes 1,3,5) or
pcDNA3 vector (lanes 2,4,6), were lysed (lanes 1,2) and immunopre-
cipitated with antiserum against L1 integrin chain (lanes 3,4) or
with non-immune serum (lanes 5,6). Immunoprecipitated samples
were electrophoresed on 9% SDS-PAGE and analyzed by Western
blot with 1 Wg/ml of R4 anti-uPA-R antibody.
Fig. 4. Resistance of uPA-R to cleavage. ARO and TAD-2 cells,
grown in the presence (lanes 2^6 and 8^12) or in absence (lanes 1,7)
of cl5 antibody, were incubated with medium (lanes 1^2,7^8) or
treated with 1038 M uPA (lanes 3,9), 1037 M and 1036 M plasmin
(lanes 4,10 and 5,11, respectively), 1 mg/ml chymotrypsin (lanes
6,12) for 2 h at 37‡C. Cells were then lysed, electrophoresed on 9%
SDS-PAGE and analyzed by Western blot with 1 Wg/ml of R4 anti-
body.
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by TAD-2 cells after deglycosylation was 18 kDa (Fig. 5, lane
3).
The higher glycosylation of ARO uPA-R could protect the
receptor from the e¡ect of proteolytic enzymes, thus explain-
ing its resistance to cleavage.
4. Discussion
uPA-R is expressed in a wide variety of normal and tumor
cells. Its overexpression inhibits the normal ligand binding
function of L1 integrins, thus decreasing cell adhesion to
some components of the ECM, such as ¢bronectin (FNT)
and collagen (CGN), and increasing cell adhesion to VTN,
a component of ECM associated with malignant tumors [7].
These e¡ects are induced by the physical interaction of uPA-R
with active L1 integrins and caveolin [7]. Moreover, uPA-R
can be ‘activated’ by uPA, which promotes cell surface pro-
teolytic activity [5] and uPA-R binding to VTN [6]. All these
events must be tightly regulated, since they can increase the
invasive potential of cells [1]. We have therefore investigated
whether uPA-R cleavage could represent a regulatory step of
these uPA-R activities.
We have previously shown that a cleaved form of uPA-R,
lacking the uPA binding domain, is strongly expressed on the
surface of normal thyroid cells and in benign thyroid tumors,
whereas it is reduced or absent in more aggressive tumor
thyroid cells, such as follicular and anaplastic thyroid carci-
noma-derived cells [14].
We now report the association of intact uPA-R with L1
integrins in thyroid cells as well, and show that uPA-R cleav-
age abolishes most of this association. The observation that
very low amounts of cleaved uPA-R still interact with L1
integrins could indicate that cleaved uPA-R retains its ability
to bind integrins, but with a much lower a⁄nity than intact
uPA-R. Therefore uPA-R cleavage represents the physiologi-
cal mechanism regulating the physical interaction between
uPA-R and L1 integrins. Since uPA-R interaction with L1
integrins plays an important role in integrin-mediated adhe-
sion and signaling [7,18], we suggest that both these processes
are indirectly regulated by uPA-R cleavage. Our hypothesis is
also supported by the recent observation that soluble intact
uPA-R functionally interacts with L2 integrins in the binding
to I-CAM molecule on endothelial cells, whereas the soluble
cleaved form does not [19].
Cleaved uPA-R disappears in more aggressive carcinoma
cells, such as follicular and anaplastic carcinomas [14]. We
now report that anaplastic carcinoma ARO cells express a
cleavage-resistant form of uPA-R, which is more glycosylated
than the cleavage-sensitive uPA-R expressed by normal thy-
roid TAD-2 cells. We propose that glycosylation could regu-
late uPA-R cleavage by masking uPA-R sites sensitive to pro-
teolytic enzymes such as uPA and plasmin. Indeed,
glycosylation variants of uPA-R have been widely described
in the past [20], although they have only been related to a
lower a⁄nity of uPA-R for its traditional ligand uPA [21].
uPA-R cleavage could thus represent a sort of negative
regulation of the uPA-R-mediated invasive potential of the
cell. In normal cells, uPA cleaves uPA-R, thus reducing cell
surface proteolytic activity and cell adhesion to VTN, and, at
the same time, allowing integrin-mediated cell binding to
physiological components of ECM (FNT and CGN). In
fact, intact uPA-R is required for binding to active uPA,
VTN and L1 integrins. In addition, cleaved uPA-R is not
simply an inactive degradation product of uPA-R, but a che-
moattractant for macrophages, T-lymphocytes, etc. [22,23],
and therefore could be actively involved in immunological
processes. Aggressive tumor cells could escape this regulatory
mechanism by more heavily glycosylating uPA-R, thus be-
coming advantaged in the process of migration and tissue
invasion. In fact, uPA is able to bind cleavage-resistant
uPA-R, thus increasing both cell surface proteolysis and
uPA-R-mediated, high a⁄nity cell adhesion to VTN. More-
over, intact uPA-R is able to decrease integrin-mediated cell
adhesion to FNT and CGN, by interacting with L1 integrins.
The characterization of uPA-R cleavage as a regulatory
mechanism of uPA-R ‘activities’, and its regulation by glyco-
sylation, could represent an important step in the elucidation
of the role of uPA-R in tumor invasion and metastasis.
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